Status:
COMPLETED
Randomized, Double-Blind, Placebo-Controlled, Forced-Titration, Comparing Telmisartan vs Valsartan. Taken Orally for Eight Weeks in Patients With Stage 1 and Stage 2 Hypertension
Lead Sponsor:
Boehringer Ingelheim
Conditions:
Hypertension
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The primary objective of this study is to compare the effectiveness of telmisartan 80 mg / hydrochlorothiazide 25 mg \[Micardis HCT\] to valsartan 160 mg / hydrochlorothiazide 25 mg \[Diovan HCT\] and...
Eligibility Criteria
Inclusion
- Ability to provide written informed consent.
- Age 18 years or older
- Ability to stop current antihypertensive therapy without unacceptable risk to the patient (investigator's discretion)
- Seated cuff DBP of ? 95 mmHg at Visit 2 (baseline)
Exclusion
- Pre-menopausal women (last menstruation ? 1 year prior to start of run-in period) who:
- are not surgically sterile and/or
- are nursing or pregnant
- are of child-bearing potential and are NOT practicing acceptable means of birth control, do NOT plan to continue using this method throughout the study and do NOT agree to submit to periodic pregnancy testing during participation in studies of \> 3-months duration. Acceptable methods of birth control include oral, implantable, transdermal, or injectable contraceptives, and Intra-Uterine Device (IUD).
- Known or suspected secondary hypertension.
- Mean seated SBP \>= 180 mmHg or mean seated DBP \>= 120 mmHg during any clinic visit prior to randomization.
- Hepatic and/or renal dysfunction as defined by the following laboratory parameters:
- SGPT (ALT) or SGOT (AST) \> 2 times the upper limit of normal range, or
- Serum creatinine \> 3.0 mg/dL or creatinine clearance \< 0.6 ml/sec.
- Bilateral renal artery stenosis, renal artery stenosis in a solitary kidney, post-renal transplant or with only one kidney.
- Clinically relevant hypokalemia or hyperkalemia.
- Uncorrected volume depletion.
- Uncorrected sodium depletion.
- Primary aldosteronism.
- Hereditary fructose intolerance.
- Biliary obstructive disorders, cholestatis or moderate to severe hepatic in sufficiency.
- Patients who have previously experienced symptoms characteristic of angioedema during treatment with ACE inhibitors or angiotensin II receptor antagonists.
- History of drug or alcohol dependency within six months prior to start of run-in period.
- Chronic administration of any medications known to affect blood pressure, exc
Key Trial Info
Start Date :
September 1 2005
Trial Type :
INTERVENTIONAL
End Date :
July 1 2006
Estimated Enrollment :
1185 Patients enrolled
Trial Details
Trial ID
NCT00168779
Start Date
September 1 2005
End Date
July 1 2006
Last Update
December 28 2017
Active Locations (113)
Enter a location and click search to find clinical trials sorted by distance.
1
502.476.074 Boehringer Ingelheim Investigational Site
Athens, Alabama, United States
2
502.476.059 Boehringer Ingelheim Investigational Site
Birmingham, Alabama, United States
3
502.476.071 Boehringer Ingelheim Investigational Site
Birmingham, Alabama, United States
4
502.476.079 Boehringer Ingelheim Investigational Site
Birmingham, Alabama, United States